Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | APAF1 | O14727 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | HK1 | P19367 | 1/20 | 0.34 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10092631 | 0.73 | ENPP2 (0.40) | ENPP2 | |
| Boric Acid SCHEMBL28809555 | 0.73 | NAPRT (0.45) | L3MBTL1ENPP2ADRA2AADRA2BADRA2C | |
| SCHEMBL29954840 | 0.73 | ENPP2 (0.40) | ENPP2RAB9AMAPTLMNAKMT2A | |
| SCHEMBL14769188 | 0.71 | ORAI1 (0.37) | RAB9A | |
| SCHEMBL29958138 | 0.71 | CCR1 (0.48) | L3MBTL1ADRA2AADRA2BADRA2CPLAU | |
| SCHEMBL12004168 | 0.71 | ALDH1A1 (0.43) | ADRA2AADRA2BADRA2CPLAUFDPS | |
| SCHEMBL29956057 | 0.71 | ADRA2A (0.42) | ENPP2ADRA2AADRA2BADRA2CRAB9A | |
| SCHEMBL28375630 | 0.71 | ADRA2A (0.42) | ENPP2ADRA2AADRA2BADRA2CRAB9A | |
| SCHEMBL200776 | 0.71 | CCR1 (0.48) | L3MBTL1ADRA2AADRA2BADRA2CPLAU | |
| SCHEMBL29681228 | 0.71 | ORAI1 (0.37) | RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528788-B2 | Pesticidally active benzene- and azine-amide compounds | SYNGENTA CROP PROTECTION AG (CH) | 2026-01-20 | — | — | US | disclosed |
| EP-4676476-A1 | INHIBITORS OF TDP-43 AND TAU AGGREGATION | Aquinnah Pharmaceuticals, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| US-20250134890-A1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | UCB Biopharma SRL (BE) | 2025-05-01 | — | — | US | disclosed |
| US-12239643-B2 | Therapeutic agent for inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2025-03-04 | — | — | US | disclosed |
| CN-119504607-A | Organic compound, application thereof and organic electroluminescent device | 北京绿人科技有限责任公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-112839933-B | Pesticidally active benzene-amide and azine-amide compounds | 先正达参股股份有限公司 | 2024-12-13 | — | — | CN | disclosed |
| WO-2024208315-A1 | AROMATIC HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 中国医药研究开发中心有限公司 | 2024-10-10 | — | — | WO | disclosed |
| US-20240336627-A1 | NOVEL COMPOUNDS FOR THE DIAGNOSIS OF TDP-43 PROTEINOPATHIES | AC IMMUNE SA (CH) | 2024-10-10 | — | — | US | disclosed |
| WO-2024187126-A1 | INHIBITORS OF TDP-43 AND TAU AGGREGATION | AQUINNAH PHARMACEUTICALS, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| EP-4370521-A1 | NOVEL COMPOUNDS FOR THE DIAGNOSIS OF TDP-43 PROTEINOPATHIES | AC Immune SA (CH) | 2024-05-22 | — | — | EP | disclosed |
| EP-2785707-A1 | NOVEL 2H-INDAZOLES AS EP2 RECEPTOR ANTAGONISTS | Bayer Intellectual Property GmbH (DE) | 2014-10-08 | — | — | EP | disclosed |
| EP-2670738-A2 | 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-12-11 | — | — | EP | disclosed |
| WO-2013079425-A1 | NOVEL 2H-INDAZOLES AS EP2 RECEPTOR ANTAGONISTS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-06 | — | — | WO | disclosed |
| US-8399459-B2 | 1,4 oxazines as BACE1 and/or BACE2 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-03-19 | — | — | US | disclosed |
| WO-2012104263-A2 | 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | WO | disclosed |
| US-20120196863-A1 | 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | SIENA BIOTECH S.P.A. (IT) | 2012-08-02 | — | — | US | disclosed |
| US-20110178064-A1 | SPIRO CONDENSED BARBITURIC ACID DERIVATIVES FOR USE AS ANTIBACTERIAL | ASTRAZENECA R&D (SE) | 2011-07-21 | — | — | US | disclosed |
| EP-2178876-A1 | SPIRO CONDENSED BARBITURIC ACID DERIVATIVES FOR USE AS ANTIBACTERIAL | AstraZeneca AB (SE) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009010801-A1 | SPIRO CONDENSED BARBITURIC ACID DERIVATIVES FOR USE AS ANTIBACTERIAL | ASTRAZENECA UK LIMITED (GB) | 2009-01-22 | — | — | WO | disclosed |
| WO-2007044085-A2 | HETEROARYL COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178064-A1 | SPIRO CONDENSED BARBITURIC ACID DERIVATIVES FOR USE AS ANTIBACTERIAL | TBCA, TUBA1A, BROX | L3MBTL1 4446/4885ENPP2 4594/4885ADRA2A 1403/4885 |
| US-12528788-B2 | Pesticidally active benzene- and azine-amide compounds | CBR3, CBR1, DDT | L3MBTL1 461/4885ENPP2 4362/4885ADRA2A 543/4885 |
| US-20120196863-A1 | 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | BACE2, BACE1, PSEN1 | L3MBTL1 4643/4885ENPP2 619/4885ADRA2A 597/4885 |
| US-20240336627-A1 | NOVEL COMPOUNDS FOR THE DIAGNOSIS OF TDP-43 PROTEINOPATHIES | TARDBP, FUS, MAPT | L3MBTL1 513/4885ENPP2 3893/4885ADRA2A 4370/4885 |
| US-20250134890-A1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | G6PD, DPYD, DHFR | L3MBTL1 744/4885ENPP2 325/4885ADRA2A 3076/4885 |
| US-12239643-B2 | Therapeutic agent for inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases | CCR1, SSB, C5 | L3MBTL1 1379/4885ENPP2 155/4885ADRA2A 2329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.